Reactogenicity and Immunogenicity of a Protein-Conjugated Pneumococcal Oligosaccharide Vaccine in Older Adults

• Published in: The Journal of infectious diseases Vol. 173; no. 4; pp. 1014 - 1018
• Main Authors: Powers, Douglas C., Anderson, Edwin L., Lottenbach, Kathleen, Mink, ChrisAnna M.
• Format: Journal Article
• Language: English
• Published: Chicago, IL The University of Chicago Press 01.04.1996; University of Chicago Press
• Subjects: Aged; Antibodies; Antibodies, Bacterial - immunology; Antigens; Bacterial Capsules - immunology; Bacterial diseases; Bacterial diseases of the respiratory system; Bacterial Vaccines - adverse effects; Bacterial Vaccines - immunology; Biological and medical sciences; Concise Communications; Corynebacterium diphtheriae; Corynebacterium diphtheriae - immunology; Female; Geometric mean; Human bacterial diseases; Humans; Immune response; Immunization; Immunoglobulin G - immunology; Infectious diseases; Male; Medical sciences; Middle Aged; Older adults; Oligosaccharides; Oligosaccharides - immunology; Pneumococcal vaccine; Polysaccharides; Streptococcus pneumoniae - immunology; Time Factors; Vaccination; Human; Immune response; Toxicity; Vaccination; Vaccine; Streptococcus pneumoniae; Prevention; Streptococcaceae; Immunoprophylaxis; Immunogenicity; Efficiency; Bacteria; Micrococcales; Adult; Public health
• ISSN: 0022-1899; 1537-6613
• DOI: 10.1093/infdis/173.4.1014

Healthy adults ⩾50 years old were immunized with either pentavalent Corynebacterium diphtheriae C7 (β197) cross-reactive material (CRM197) protein-conjugated pneumococcal vaccine (CV) containing 10 µg each of capsular oligosaccharides from serotypes 6B, 14, 18C, 19F, and 23F or with licensed (23-valent, 25 µg/serotype) pneumococcal polysaccharide vaccine (PV). Adverse reactions, predominantly local in nature, occurred in 20 of 23 CV recipients versus 13 of 23 PV recipients (P < .05). Compared with mean postvaccination antibody concentrations in PV recipients, those induced by CV were not significantly different for serotypes 6B, 14, 18C, and 23F and were lower for 19F (P < .05). Six months later, reimmunization with PV of subjects who had initially received CV elicited a slight boost in antibody concentrations to levels that were not significantly higher than those achieved after the primary vaccination or than those in persons given a single dose of PV. Pneumococcal vaccines containing protein-conjugated oligosaccharides may offer no advantage over currently licensed preparations containing unconjugated polysaccharides for immunization of healthy older adults.